Both the low and high accumulated dosage treatments with anti-TNF-α agents were associated with an increased risk of infection-related hospitalization (HR = 4.0, 95% CI: 2.9–5.5 in the low accumulated dosage group, HR = 3.3, 95% CI: 2.4–4.5 in the high accumulated dosage group). The gene discussed is TNF; the disease is infection.